SG10201606883QA - Benzofuran compounds for the treatment of hepatitis c virus infections - Google Patents

Benzofuran compounds for the treatment of hepatitis c virus infections

Info

Publication number
SG10201606883QA
SG10201606883QA SG10201606883QA SG10201606883QA SG10201606883QA SG 10201606883Q A SG10201606883Q A SG 10201606883QA SG 10201606883Q A SG10201606883Q A SG 10201606883QA SG 10201606883Q A SG10201606883Q A SG 10201606883QA SG 10201606883Q A SG10201606883Q A SG 10201606883QA
Authority
SG
Singapore
Prior art keywords
hepatitis
treatment
virus infections
benzofuran compounds
benzofuran
Prior art date
Application number
SG10201606883QA
Other languages
English (en)
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201606883Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SG10201606883QA publication Critical patent/SG10201606883QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201606883QA 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections SG10201606883QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
SG10201606883QA true SG10201606883QA (en) 2016-10-28

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201606883QA SG10201606883QA (en) 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections

Country Status (37)

Country Link
US (2) US8927593B2 (de)
EP (2) EP2744332B1 (de)
JP (2) JP6367712B2 (de)
KR (1) KR101913800B1 (de)
CN (1) CN103732065B (de)
AR (1) AR087563A1 (de)
AU (1) AU2012299295B2 (de)
BR (1) BR112014002845A2 (de)
CA (1) CA2844086A1 (de)
CL (2) CL2014000393A1 (de)
CO (1) CO6862153A2 (de)
CR (1) CR20140078A (de)
CY (1) CY1118399T1 (de)
DK (1) DK2744332T3 (de)
DO (1) DOP2014000034A (de)
EA (1) EA032841B1 (de)
ES (1) ES2611731T3 (de)
HR (1) HRP20161743T1 (de)
HU (1) HUE030300T2 (de)
IL (1) IL230487B (de)
IN (1) IN2014CN00572A (de)
JO (1) JO3281B1 (de)
LT (1) LT2744332T (de)
MA (1) MA35443B1 (de)
ME (1) ME02588B (de)
MX (1) MX354676B (de)
PE (1) PE20141201A1 (de)
PL (1) PL2744332T3 (de)
PT (1) PT2744332T (de)
RS (1) RS55462B1 (de)
SG (1) SG10201606883QA (de)
SI (1) SI2744332T1 (de)
SM (1) SMT201700028B (de)
TW (1) TWI538915B (de)
UY (1) UY34274A (de)
WO (1) WO2013028371A1 (de)
ZA (1) ZA201401020B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606646RA (en) 2011-08-17 2016-09-29 Glaxosmithkline Llc Therapeutic methods
IN2014CN00572A (de) 2011-08-19 2015-04-03 Glaxo Group Ltd
MX2017006138A (es) 2014-11-10 2017-11-16 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas de accion prolongada para hepatitis c.
SG11201703646SA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Combination long acting compositions and methods for hepatitis c
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
EP3589630B1 (de) * 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclische sulfamidverbindungen und verfahren zur verwendung davon
EP3740489A1 (de) * 2018-01-17 2020-11-25 GlaxoSmithKline Intellectual Property Development Limited Pi4kiiibeta-hemmer
CA3155559A1 (en) * 2019-10-25 2021-04-29 Sachiko Koike Novel substituted condensed ring compound
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2376965A1 (en) 1999-07-07 2001-01-11 Timothy Patrick Forsyth Peptide boronic acid inhibitors of hepatitis c virus protease
JP4162491B2 (ja) 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
CN1731993A (zh) 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
CA2631024A1 (en) 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
KR101819869B1 (ko) 2006-02-16 2018-01-17 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
US8106031B2 (en) * 2006-05-02 2012-01-31 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
EP2532643A1 (de) * 2007-06-08 2012-12-12 MannKind Corporation IRE-1a-Inhibitoren
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
RU2010137635A (ru) * 2008-02-14 2012-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические антивирусные соединения
EP2187893A4 (de) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc Kleine boronhaltige moleküle als entzündungshemmende wirkstoffe
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
EP2348863A4 (de) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Borhaltige kleine moleküle
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
TW201138786A (en) 2010-02-19 2011-11-16 Glaxo Group Ltd Therapeutic compounds
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
AU2011329485A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
SG10201606646RA (en) * 2011-08-17 2016-09-29 Glaxosmithkline Llc Therapeutic methods
IN2014CN00572A (de) 2011-08-19 2015-04-03 Glaxo Group Ltd

Also Published As

Publication number Publication date
PT2744332T (pt) 2017-01-24
PL2744332T3 (pl) 2017-03-31
WO2013028371A1 (en) 2013-02-28
MA35443B1 (fr) 2014-09-01
CR20140078A (es) 2014-03-20
US8927593B2 (en) 2015-01-06
DOP2014000034A (es) 2014-06-01
MX354676B (es) 2018-03-15
CO6862153A2 (es) 2014-02-10
DK2744332T3 (en) 2017-01-16
MX2014001989A (es) 2014-02-27
EP3199531A1 (de) 2017-08-02
US20150080343A1 (en) 2015-03-19
KR20140054287A (ko) 2014-05-08
JP2017125010A (ja) 2017-07-20
UY34274A (es) 2013-04-05
EA201490213A1 (ru) 2014-07-30
TW201321390A (zh) 2013-06-01
JO3281B1 (ar) 2018-09-16
JP2014527529A (ja) 2014-10-16
RS55462B1 (sr) 2017-04-28
IN2014CN00572A (de) 2015-04-03
CA2844086A1 (en) 2013-02-28
SI2744332T1 (sl) 2017-01-31
CN103732065B (zh) 2016-10-26
ES2611731T3 (es) 2017-05-10
EA032841B1 (ru) 2019-07-31
HRP20161743T1 (hr) 2017-02-24
KR101913800B1 (ko) 2018-11-01
ZA201401020B (en) 2020-11-25
EP2744332A4 (de) 2015-01-14
EP2744332B1 (de) 2016-10-26
US9682999B2 (en) 2017-06-20
JP6367712B2 (ja) 2018-08-01
CL2017000293A1 (es) 2017-10-06
IL230487B (en) 2019-06-30
AU2012299295A1 (en) 2014-02-20
AU2012299295B2 (en) 2016-03-31
US20130237501A1 (en) 2013-09-12
TWI538915B (zh) 2016-06-21
BR112014002845A2 (pt) 2017-02-21
LT2744332T (lt) 2017-01-10
CL2014000393A1 (es) 2014-08-01
ME02588B (de) 2017-06-20
HUE030300T2 (en) 2017-04-28
CN103732065A (zh) 2014-04-16
PE20141201A1 (es) 2014-10-03
EP2744332A1 (de) 2014-06-25
CY1118399T1 (el) 2017-06-28
IL230487A0 (en) 2014-03-31
SMT201700028B (it) 2017-03-08
AR087563A1 (es) 2014-04-03

Similar Documents

Publication Publication Date Title
HK1256490A1 (zh) 用於治療病毒感染的嘧啶衍生物
HK1211589A1 (en) Compounds for the treatment of paramoxyvirus viral infections
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
ZA201401020B (en) Benzofuran compounds for the treatment of hepatitis c virus infections
HK1197400A1 (zh) 治療 的化合物
HK1191935A1 (en) Spiro compounds as hepatitis c virus inhibitors
EP2753611A4 (de) Substituierte benzofuranverbindungen und verfahren zu ihrer verwendung für die behandlung von virenerkrankungen
ZA201205547B (en) Therapies for treating hepatitis c virus infection
IL233899A0 (en) Macrocyclic compounds for suppression of hepatitis C virus replication
HRP20190393T1 (hr) Pripravak protutijela namijenjen sprječavanju ili liječenju infekcije mutantnim virusom hepatitisa b
ZA201308011B (en) Processes for preparing inhibitors of the hepatitis c virus
ZA201306342B (en) The treatment of viral infections
ME02682B (de) Piperazin-piperidin-verbindungen als hepatitis-c-virus-inhibitoren
HK1205680A1 (en) Agent for the treatment of hepatitis c virus
SG10201602184TA (en) Treatment of hepatitis c virus infection with alisporivir
GB201217331D0 (en) Novel compound useful for the treatment of infectious diseases
GB201114710D0 (en) Treatment of hepatitis c